Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP-1929 photoimmunotherapy plus pembrolizumab in recurrent head and neck cancer
NCT06699212Phase 3Recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- Dec 2024
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Light/Condition-Responsive Prodrugs
- Countries
- 3
01
Overview
A Phase 3 trial of cetuximab sarotalocan sodium in head and neck squamous cell carcinoma (HNSCC), sponsored by Rakuten Medical, Inc.. Started Dec 2024; status: recruiting.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06699212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699212.